Navigation Links
Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
Date:1/15/2008

Study Designed to Determine Statin Effects on Regression of Atherosclerosis

CLEVELAND, Jan. 15 /PRNewswire/ -- Cleveland Clinic researchers will coordinate the first head-to-head comparison of the two most powerful statin medications. The trial intends to begin enrollment as early as next week. Statins are the world's most commonly prescribed drugs and widely used to treat patients with elevated cholesterol levels.

The two drugs, atorvastatin (Lipitor) and rosuvastatin (Crestor), lower LDL ("bad") cholesterol and raise HDL ("good") cholesterol. But which drug is best for patients with heart disease? This study will seek to answer this important scientific question by measuring the rate of regression of coronary disease using intravascular ultrasound (IVUS), a technique that directly measures the amount of plaque in the coronary arteries.

The SATURN study (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) will compare the ability of these two statins to stop the progression of atherosclerosis, the main cause of cardiovascular disease, over a two year treatment period.

SATURN, a multicenter, double-blind Phase IIIb trial, will use IVUS imaging to study approximately 1,300 patients at 150 hospitals in 20 countries worldwide. The trial is expected to be completed in 2011. Cleveland Clinic cardiologist Stephen J. Nicholls, M.D., PhD., will lead the trial.

Cleveland Clinic researchers have conducted two previous studies with IVUS looking at statins and the rate of atherosclerosis regression. Researchers have found a significant benefit with statins by intensively lowering LDL- cholesterol and the inflammatory marker C-reactive protein (CRP) and by raising levels of HDL cholesterol. SATURN aims to determine if differences in the ability of the different statins to lower LDL and raise HDL can promote regression (reduction in the amount of plaque in the coronary arteries).

About Cleveland Clinic

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic in 2006. Cleveland Clinic's Web site address is http://www.clevelandclinic.org .


'/>"/>
SOURCE Cleveland Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
Breaking Medicine News(10 mins):